Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.

A mutation in the peroxisome proliferator-activated receptor gamma2 (PPARgamma2) gene with a cytosine to guanine substitution results in an exchange of proline (Pro) with alanine (Ala) in exon B (codon 12) of this gene. This polymorphism has been associated with high insulin sensitivity and low body weight, but no data have been published to date about its effect on early atherosclerosis. We investigated the relationship of the Pro(12)Ala polymorphism to early atherosclerosis, measured by the intima-media thickness (IMT). A total of 622 subjects were included, aged 40-70 yr, who were participants of the RIAD (Risk factors in Impaired glucose tolerance for Atherosclerosis and Diabetes) study and were at risk of developing type 2 diabetes. Altogether, 449 of the subjects had the common genotype (Pro(12)Pro), 162 had the Pro(12)Ala genotype, and 11 the Ala(12)Ala genotype. IMT was significantly decreased in subjects with the Ala(12)Ala genotype compared with subjects with the other two genotypes. Body mass index, free fatty acid levels, and leukocyte count were lower in subjects with the Ala(12)Ala genotype compared with subjects with the Pro(12)Pro or Pro(12)Ala genotypes. In multivariate analysis, the Ala(12)Ala genotype was a significant independent determinant of IMT. Furthermore, we demonstrated specific expression of the PPARgamma2 gene in human atherosclerotic lesions as well as in cultured primary macrophages and foam cells. In conclusion, our data suggest that the Ala(12)Ala genotype of the PPARgamma2 gene may protect from early atherosclerosis in subjects at risk for diabetes.

[1]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[2]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[3]  J. Pankow,et al.  Regarding "Testing for population subdivision and association in four case-control studies". , 2002, American journal of human genetics.

[4]  Q. Ren,et al.  Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. , 2001, The Journal of clinical endocrinology and metabolism.

[5]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[6]  K. Clément,et al.  The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes , 2000, International Journal of Obesity.

[7]  Eric S. Lander,et al.  The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.

[8]  M. Laakso,et al.  Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. , 1999, The Journal of clinical endocrinology and metabolism.

[9]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[10]  T. Kadowaki,et al.  The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 Diabetes , 2000 .

[11]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[12]  H. Häring,et al.  The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects , 1999, Diabetologia.

[13]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[14]  T. Jørgensen,et al.  Studies of the Pro12Ala polymorphism of the ppar-γ gene in the Danish MONICA cohort: Homozygosity of the Ala allele confers a decreased risk of the Insulin Resistance syndrome , 2002 .

[15]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[16]  T. Temelkova-Kurktschiev,et al.  Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals , 1998, Diabetologia.

[17]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[18]  Evaluation of arteriosclerosis progression with ultrasonic biopsy and intima-media thickness measurements. , 1993, VASA. Zeitschrift fur Gefasskrankheiten.

[19]  M. Kasuga,et al.  The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. , 2001, Diabetes.

[20]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[21]  J. Auwerx,et al.  Transcription, adipocyte differentiation, and obesity , 1996, Journal of Molecular Medicine.

[22]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[23]  J. Salonen,et al.  Measurement of intima-media thickness of common carotid arteries with high-resolution B-mode ultrasonography: inter- and intra-observer variability. , 1991, Ultrasound in medicine & biology.

[24]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[25]  K. Lunetta,et al.  Testing for population subdivision and association in four case-control studies. , 2002, American journal of human genetics.

[26]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[27]  T Gustavsson,et al.  Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. , 1991, Clinical physiology.

[28]  V. Colantuoni,et al.  Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. , 1999, Diabetes.

[29]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[30]  M. Stumvoll,et al.  Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. , 2001, Diabetes.

[31]  M. Yamauchi,et al.  Another potential use of troglitazone in noninsulin-dependent diabetes mellitus. , 1998, The Journal of clinical endocrinology and metabolism.

[32]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[33]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[34]  P Pignoli,et al.  Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.

[35]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F. Collins,et al.  The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. , 2001, Diabetes.

[37]  J. Auwerx,et al.  Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus , 2000, International Journal of Obesity.

[38]  K. Anderson,et al.  White blood cell count and cardiovascular disease. Insights from the Framingham Study. , 1992, JAMA.

[39]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.